Farletuzumab ecteribulin(FRα抗体偶联药物)在晚期实体瘤中的1/2期剂量探索研究
这项开放标签、多中心1/2期研究评估了靶向叶酸受体α(FRα)的抗体偶联药物FZEC在经治实体瘤患者中的安全性与抗肿瘤活性。25 mg/m2队列中ILD/肺炎均为1/2级,33 mg/m2因ILD/肺炎停止评估。分次给药(8 mg/m2 D1/D8/D15)未出现ILD/肺炎且缓解更多,但亚组样本量小。
要点
- 剂量递增阶段ILD/肺炎发生率为40%,促使后续改为按体表面积给药。
- 25 mg/m2队列ILD/肺炎均为1/2级,33 mg/m2因ILD/肺炎停止评估。
- 8 mg/m2 D1/D8/D15分次给药未出现ILD/肺炎且缓解更多,但亚组样本量小。
核心结论
- FZEC分次给药可降低ILD/肺炎风险并显示初步抗肿瘤活性。
- 后续剂量优化B部分将测试其他分次剂量方案(单药及联合仑伐替尼)及同步激素使用。
研究设计与样本
- 开放标签、多中心1/2期剂量探索研究,注册号NCT04300556。
- 剂量递增阶段纳入卵巢癌、子宫内膜癌、三阴性乳腺癌和非小细胞肺癌,剂量为0.9 mg/kg和1.2 mg/kg IV Q3W。
- 剂量确认阶段纳入卵巢癌/子宫内膜癌,剂量为25 mg/m2和33 mg/m2 IV Q3W。
- 剂量优化A部分评估8 mg/m2 D1/D8/D15、12 mg/m2 D1/D8及25 mg/m2 D1+静脉激素Q3W。
主要发现
- 剂量递增阶段(n=25)ILD/肺炎发生率为40%。
- 剂量确认阶段(n=24)ILD/肺炎发生率为33.3%。
- 25 mg/m2队列中所有ILD/肺炎事件均为1/2级。
- 33 mg/m2剂量评估因观察到ILD/肺炎而停止。
- 接受8 mg/m2 D1/D8/D15的患者未发生ILD/肺炎,且与其他方案相比缓解更多,但亚组样本量小。
关键数值与推荐
- 卵巢癌患者中88.7%和子宫内膜癌患者中50.0%既往接受过≥2线抗肿瘤治疗。
- 剂量递增阶段ILD/肺炎发生率为40%(n=25)。
- 剂量确认阶段ILD/肺炎发生率为33.3%(n=24)。
- 25 mg/m2队列ILD/肺炎均为1/2级。
- 33 mg/m2因ILD/肺炎停止评估。
临床怎么用
- FZEC分次给药策略可降低ILD/肺炎风险,支持进一步开发。
- 同步激素使用可能延迟ILD/肺炎起病,但发生率相似。
- 8 mg/m2 D1/D8/D15方案未出现ILD/肺炎且缓解更多,但需更大样本验证。
局限性
- 亚组样本量小,尤其是分次给药方案的比较。
- 剂量递增阶段未采用按体表面积给药,ILD/肺炎发生率较高。
- 33 mg/m2剂量因毒性停止评估,未能获得完整剂量-效应数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In this phase 1/2 study, we assessed the safety/antitumor activity of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in patients with pretreated solid tumors. METHODS: Patients aged ≥18 years with measurable disease (per RECIST v1.1) were included. Patients with ovarian cancer (OC), endometrial cancer (EC), TNBC, and NSCLC were included in Dose-Escalation (0.9 mg/kg and 1.2 mg/kg IV Q3W). Patients with OC/EC were included for Dose-Confirmation (25 mg/m2 and 33 mg/m2 IV Q3W) and Dose-Optimization-part-A (8 mg/m2 D1/D8/D15, 12 mg/m2 D1/D8; 25 mg/m2 D1 + steroid IV Q3W). RESULTS: Eighty-nine patients were enrolled (median age: 67.0 years); most (88.7%) patients with OC and 50.0% patients with EC received ≥2 previous anticancer regimens. In Dose-Escalation (n = 25), interstitial lung disease (ILD)/pneumonitis occurred in 40% of patients. The dosing methodology was amended to body surface area-based dosing in subsequent study parts as an ILD/pneumonitis-mitigation strategy. In Dose-Confirmation (n = 24), 33.3% of patients experienced ILD/pneumonitis. In the 25 mg/m2 cohort, all ILD/pneumonitis events were grade-1/2. Evaluation of the 33 mg/m2 dose was discontinued due to observed ILD/pneumonitis. Dose equivalents of 25 mg/m2 were further evaluated in Dose-Optimization-part-A, with steroids/fractionated dosing (to mitigate ILD/pneumonitis). Patients receiving 8 mg/m2 D1/D8/D15 experienced no ILD/pneumonitis and achieved more responses versus other regimens, but the subgroup sizes were small. With steroids, incidence of ILD/pneumonitis was similar, but onset appeared delayed. CONCLUSIONS: Fractionated doses of FZEC reduced the risk of ILD/pneumonitis and showed preliminary antitumor activity. Dose-Optimization-part-B will test additional FZEC fractionated doses (alone and in combination with lenvatinib) and concomitant steroid use. Clinical Trial Registration #: NCT04300556.
引用
- Wenham RM, Ray-Coquard I, Kristeleit R, et al. Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study. Gynecol Oncol. 2026. PMID: 42833056. doi:10.1016/j.ygyno.2026.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。